Self-monitoring of blood glucose in diabetic patients: from the least common denominator to the greatest common multiple

Diabetes & Metabolism
L MonnierHélène Boniface

Abstract

Self-monitoring of blood glucose (SMBG) is recognized as necessary in insulin-treated diabetic patients. There is less evidence for the regular use of SMBG in non-insulin-using type 2 diabetic patients. The rationale for an appropriate regimen of SMBG might be to have at least one time-point of monitoring included within each of the 3 periods of daytime i.e. fasting, postprandial and postabsorptive periods. Interventional trials have indicated that a 4-to 5-point daily profile represents an optimal regimen for SMBG in type 1 diabetic patients with satisfactory diabetic control. This type of SMBG includes 4 daily glucose determinations (3 before each meal and one at bedtime) and one weekly monitoring at 3: 00 am. However additional determinations should be made within postprandial states, particularly when rapid insulin analogues or pump-treatments are used. In non-insulin-using type 2 diabetic patients, studies of diurnal glycemic profiles have indicated that postprandial glucose is an important contributor to HbA1c and that mid-morning hyperglycemia is the "weakest link" of metabolic control. Therefore mid-morning glucose testing should be recommended when HbA1c levels are not correctly controlled. Furthermore, extended postlu...Continue Reading

References

Sep 3, 1992·The New England Journal of Medicine·S DinneenR Rizza
Jun 1, 1990·Diabetes Care·M C Riddle
Sep 1, 1990·Diabetes Care·R C Turner, R R Holman
Sep 30, 1993·The New England Journal of Medicine·UNKNOWN Diabetes Control and Complications Trial Research GroupC Siebert
Sep 7, 2000·European Journal of Clinical Investigation·L Monnier
Feb 27, 2004·European Journal of Clinical Investigation·L MonnierH Lapinski

❮ Previous
Next ❯

Citations

Sep 10, 2008·Current Diabetes Reports·Louis Monnier, Claude Colette
Oct 18, 2005·The American Journal of Medicine·Jaime Davidson
Dec 17, 2009·Diabetes Technology & Therapeutics·Nalinee PoolsupSomying Rattanasookchit
Jan 6, 2012·Diabetes Technology & Therapeutics·Antonio CerielloUNKNOWN Associazione Medici Diabetologi
Jun 27, 2007·Diabetes, Obesity & Metabolism·T ParknerJ S Christiansen
Aug 10, 2010·Acta Diabetologica·Rudolf ChlupJosef Bartek
Jan 30, 2015·Current Medical Research and Opinion·Subhankar ChowdhuryEng Kiat Tan
Mar 6, 2007·La Presse médicale·Amélie TielmansPierre-Jean Guillausseau
Oct 22, 2008·Expert Opinion on Pharmacotherapy·Louis Monnier, Claude Colette
Nov 13, 2009·Diabetes Care·Louis Monnier, Claude Colette
Aug 16, 2015·Journal of Correctional Health Care : the Official Journal of the National Commission on Correctional Health Care·Robin N Hunter BuskeyMark N Feinglos
Nov 4, 2009·Journal of Diabetes Science and Technology·Louis MonnierDavid R Owens
Oct 1, 2009·The Diabetes Educator·Christopher G ParkinWilliam H Polonsky
Sep 13, 2006·Journal of Nutrition Education and Behavior·Lauren Lautenschlager, Chery Smith
Sep 7, 2007·Advanced Drug Delivery Reviews·Erhard Haus

❮ Previous
Next ❯

Related Concepts

Related Feeds

Autoimmune Diabetes & Tolerance

Patients with type I diabetes lack insulin-producing beta cells due to the loss of immunological tolerance and autoimmune disease. Discover the latest research on targeting tolerance to prevent diabetes.